TORONTO, Oct. 27 /CNW/ - Alegro Health Corp. (TSX-V: AGO), a provider of
medical, surgical and disability management, and clinical trial administration
services, today announced that pursuant to terms and conditions of the
Company's stock option plan, granted a total of 300,000 stock options to
Dr. Martin Barkin, Chairman of the Board of Directors. The stock options were
issued at an exercise price of $0.20. Of the 300,000 options granted,
200,000 options were granted for his role as Chairman of the Board and will
expire on October 15, 2009. The remaining 100,000 were granted for his role as
a director and will expire October 15, 2013.
About Alegro Health Corp.
Alegro Health Corp. is a leading healthcare services provider capturing
high value opportunities by providing additional access to select quality
healthcare services. Through its divisions - Disability & Rehabilitation
Management; Surgical/Hospital Services, and Drug Trial Management - Alegro is
delivering additional resources to the Canadian public healthcare services and
addressing the growing demand for private and enhanced out-of-pocket
healthcare services. With superior knowledge of the healthcare industry,
extensive and trusted relationships with payers, physicians, and government
agencies, Alegro is pursuing a vertically integrated approach and an
aggressive acquisition strategy to achieve its growth objectives. Alegro is
listed on the TSX Venture Exchange under the symbol AGO. For further
information, please visit www.alegrohealth.com.
Certain information in this press release is based on beliefs and
assumptions of the Company's senior management and information currently
available to it that may constitute forward-looking information within the
meaning of securities laws. Such statements reflect the current views of the
Company with respect to future events and are subject to certain risks and
uncertainties. Actual results, events, and performance may differ materially.
Readers are cautioned not to place undue reliance on these forward-looking
This release was prepared by management of the Company who takes full
responsibility for its contents. The TSX Venture Exchange has not
reviewed and does not accept responsibility for the adequacy or accuracy
of this news release.
For further information:
For further information: Brenda Rasmussen, President and CEO, (416)
496-6166 xt. 328, firstname.lastname@example.org; Thien Ly, Investor Relations,
(416) 815-0700 xt. 251, email@example.com; Michael Moore, Investor
Relations, (416) 815-0700 xt. 241, firstname.lastname@example.org